New research suggests that women over 55 see the biggest weight loss benefits from popular medications like Wegovy and Mounjaro – but the secret to their success goes beyond just taking the injections.
A study of nearly 60,000 people by Voy, the UK’s leading medicated weight loss program, in collaboration with Imperial College London, found that women in this age group were the most engaged in their weight loss journey. They tracked their weight six times a month and attended the most coaching sessions – on average, five per program.
The research found that people who combined medication with healthy habits – like regular weigh-ins and coaching – lost 53% more weight than those relying on medication alone.
Wegovy & Mounjaro: what you need to know
Wegovy, made by Novo Nordisk, was approved in August 2024 in Australia for obesity and overweight treatment. It has since been approved for type 2 diabetes and, more recently, heart conditions.
Mounjaro (tirzepatide), from Eli Lilly, is available in injectable vials and KwikPens. However, the company has informed the TGA that all Mounjaro vials will be unavailable until August 31, 2025.
The key to lasting weight loss
While weight loss medications have revolutionized obesity treatment, long-term success depends on more than just the injections. Research shows that consistent monitoring and lifestyle changes play a crucial role.
A 2008 study found that people who weighed themselves weekly or daily lost 1-3 BMI units more than those who did it less frequently. The latest findings confirm that tracking progress and engaging in supportive care leads to better outcomes.
The bottom line
Weight loss injections are a powerful tool, but they work best when combined with healthy habits and regular support. Women over 55 are leading the way, proving that engagement and consistency are key to lasting results.